The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...

Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip ...

Dublin-based biotech firm Aerska has raised $39m (€33m) in funding to help it advance development of its technology. Aerska is developing medicines that use RNA interference (RNAi), a ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...